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in type 2 diabetic patients and reduces
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Objective:To examine the effect of a 12-week daily treatment with 160mg of valsartan, an angiotensin II receptor blocker,
on the microcirculation and macrocirculation of type 2 diabetic patients (T2DM) and healthy subjects.
Methods: This was a prospective, randomized, double-blind, placebo-controlled crossover study. Thirteen T2DMwith no
severe complications and 13 healthy subjects completed the trial.
Results: Treatment with valsartan in T2DM improved the resting forearm skin blood flow and increased the resting
brachial artery diameter but had no effects on arterial blood pressure, large vessel vascular reactivity, or carotid
intima-media thickness. Resting skin blood flow increased by 60% (2%-90%; median and 25th-75th percentiles) during
valsartan treatment and by only 2% (22% to 27%) during placebo treatment (P< .05). No changes were observed in the
nondiabetic subjects. Immunostaining studies of forearm skin biopsy samples from T2DM and healthy subjects showed
that valsartan reduced poly(adenosine diphosphate-ribose) polymerase (PARP) activity in 50% (6/12) of the subjects.
PARP activity remained unchanged in placebo-treated subjects (P < .02). In addition, valsartan treatment increased
CD31 staining in 33% (4/12) of the subjects, whereas no change was noted in sequential skin biopsy samples of
placebo-treated subjects (P .057). Valsartan had no effect on the biochemical markers of endothelial cell activation and
other cytokines, including CAMs, interleukin 6, tumor necrosis factor , C-reactive protein, adiponectin, and plasma
activator inhibitor 1.
Conclusions: Valsartan increases the resting skin blood flow in T2DM, likely through reduction of PARP activity.
( J Vasc Surg 2006;43:760-70.)Although early studies suggested that endothelium-
independent vasodilation was normal in type 2 diabetic pa-
tients (T2DM), endothelium-dependent vasodilation is im-
paired in the skin microcirculation of T2DMwith or without
evidence of vascular complications, healthy nondiabetic sub-
jects with a parental history of T2DM, and subjects with
impaired glucose tolerance.1-3 The endothelium-dependent
vasodilation is also impaired in the macrocirculation of these
subjects as evaluated at the brachial artery.4,5
Treatment with angiotensin-converting enzyme (ACE)
inhibitors or angiotensin II receptor blockers (ARBs) has
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760been shown to improve endothelial function.6,7 ARBs have
the theoretical potential to be even more efficient with
regard to the above-mentioned end points because they
provide a sustained inhibition of the binding of angiotensin
II to the angiotensin type 1 receptor, whereas angiotensin
II levels may return to normal during chronic treatment
with ACE inhibitors. Furthermore, ARBs do not affect
signaling through the angiotensin type 2 receptor, hence
maintaining its vasodilatory and antiproliferative function.8
There is limited information of the effect of ARBs in
patients with diabetes, in particular with regard to their
effects on microcirculation.
In this study we examined the effect of valsartan, an
ARB, on the vascular reactivity of T2DM and nondiabetic
healthy subjects. Our main hypothesis was that treatment
with valsartan for 12 weeks would improve endothelial
function in both microcirculation and macrocirculation.
MATERIALS AND METHODS
Subjects. The first group of subjects included 20
healthy, nondiabetic subjects, and the second group in-
cluded 20 T2DM patients, aged 21 to 80 years. Healthy
nondiabetic subjects underwent an oral glucose tolerance
test to exclude unknown diabetes. Diabetes was defined
according to the American Diabetes Association Expert
Committee on the Classification and Diagnosis of Diabe-
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cose level of100 mg/dL and a 2-hour post–oral glucose
tolerance test plasma glucose level of 140 mg/dL were
required. Exclusion criteria included coronary artery dis-
ease, arrhythmia, heart failure (New York Heart Associa-
tion class III and IV), stroke or transient ischemic attack,
uncontrolled hypertension, macroalbuminuria, severe dys-
lipidemia (triglycerides 600 mg/dL or cholesterol 350
mg/dL), serious chronic disease that could affect the ability
of the subject to participate in the study, including long-
term diabetes complications such as blindness and lower
extremity amputation related to peripheral neuropathy
and/or peripheral arterial disease, and treatment with the
following medications: ARBs, glucocorticoids, antineo-
plastic agents, and bronchodilators.
The protocol was approved by the Institutional Review
Board at Beth Israel Deaconess Medical Center. All partic-
ipants gave written informed consent. Participants for the
study were recruited through local advertisement.
Methods. This was a prospective, randomized, double-
blind, placebo-controlled, crossover study. All participants
were evaluated during an initial screening visit and, if
suitable, were asked to return and be enrolled in the study.
The design of the study is depicted in Fig 1. The random-
ization process occurred within groups, and as a result it
was separated for the two groups. The first period lasted 12
weeks, the washout period lasted 6 weeks, and the second
period lasted 12 weeks. The baseline visit included physical
examination, blood tests, and vascular reactivity evaluation
of bothmicrocirculation andmacrocirculation. Participants
were randomized at this visit and were started on treatment
either with placebo or 160 mg of valsartan once a day. The
second visit, at the end of the first 12-week period, included
a physical examination, blood tests, and vascular reactivity
measurements. The third visit, at the end of the 6-week
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Fig 1. Schemewashout period, included physical examination, bloodtests, and vascular reactivity measurements, and each par-
ticipant was switched to the treatment opposite that of the
first period. The exit visit included physical examination,
blood tests, and vascular reactivity measurements. In all
visits, laboratory test were performed after an overnight
fast. Compliance was evaluated by counting returned
tablets.
Plasma glucose, total serum cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein choles-
terol, triglycerides, liver function tests, electrolytes, blood
urea nitrogen, and creatinine were measured by using the
Synchron CX analyzer (Beckman Coulter, Brea, Calif).
Glycosylated hemoglobin (reference range, 4%-6%) was
determined in whole blood by using ion-exchange high-
performance liquid chromatography (Tosoh 2.2, Tokyo,
Japan). Soluble intercellular adhesion molecule 1, soluble
vascular cell adhesion molecule 1, endothelin 1, tumor
necrosis factor , and soluble CD40 ligand were measured
in plasma by enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, Minn). High-sensitivity C-reactive
protein was measured by chemiluminescent immunoassay
(Life Diagnostics, West Chester, Pa). Enzyme-linked im-
munosorbent assay methods were also used to measure
plasma activator inhibitor antigen and tissue plasminogen
activator antigen (Diagnostica Stago, Parsippany, NJ), in-
terleukin 6 (Chemicon, Temecula, Calif), and adiponectin
(B-Bridge International, Sunnyvale, Calif). Routine urinal-
ysis was also performed.
Vascular reactivity tests. Tests were performed at
the Microcirculation Laboratory at the Beth Israel Dea-
coness Medical Center. These studies were performed in
a temperature-controlled room (24°C-26°C) and after a
30-minute acclimation period.
The vascular reactivity of the forearm skin microcircu-
lation was evaluated by laser Doppler perfusion imaging
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and sodium nitroprusside (endothelium-independent vaso-
dilation), as previously described.2,5 The resting blood flow
was measured at the forearm by using a laser Doppler perfu-
sion imager (Lisca PIM 2.0; Lisca Development AB, Linkop-
ing, Sweden). It uses a 1-mW helium-neon laser beam with a
633-nm wavelength that sequentially scans an area of the
tested area. The scanner was set up to scan 32 32 measure-
ment points over an area approximately 4  4 cm. Ionto-
phoresis was performed in the same area, and the skin blood
flow was measured in exactly the same area after the ionto-
phoresis (postiontophoresis blood flow measurement).
Two forearm areas were tested: one for the iontophoresis of
acetylcholine and one for sodium nitroprusside. The repro-
ducibility of this technique was previously reported by our
group. The coefficient of variation was 14.1% for the base-
line measurement and 13.7% during the maximal hyper-
emic response after the iontophoresis.1 The results of these
tests were obtained immediately after the subject left the
room. As a result, it was known whether the subject was
receiving placebo or valsartan treatment.
To assess the endothelium-dependent reactivity in the
macrocirculation, flow-mediated brachial artery dilation
was measured by using a high-resolution ultrasonograph
with a 10.0-MHz linear array transducer and an HDI
Ultramark 9 system (Advanced Technology Laboratories,
Bothel, Wash). All measurements were in accordance with
recently published guidelines.10 Reactive hyperemia was
produced by inflating a pneumatic tourniquet up to 50 mm
Hg above the systolic pressure for 5 minutes distal to the
brachial artery and then deflating it. The brachial artery diam-
eter was measured at baseline and 60 seconds after the pneu-
matic tourniquet was deflated. Endothelium-independent
vasodilation in the macrocirculation was assessed by studying
brachial artery diameter changes 5 minutes after the adminis-
tration of 400 g of sublingual nitroglycerin (nitroglycerin-
induced dilation). This test was performed 15 minutes after
the reactive hyperemia test and after a new baseline reading
was obtained. Analysis was performed by a reader (L.K.)
who was unaware of the randomization process and there-
fore did not know whether patients first received valsartan
or placebo.
Carotid measurements. The common carotid artery
intima-media thickness was measured according to previ-
ously described methods by using the same equipment that
was used for measuring the brachial artery reactivity.11
Briefly, the protocol included the scanning of the common
carotid artery, the carotid bulbs, and the proximal internal
carotid artery. All intima-media thickness measurements
(both at baseline and follow-up) were made at the same site
and angle for each subject and were performed by a very
experienced examiner, who was blinded to the supplemen-
tation status of the subjects. Ultrasound images were re-
corded on super-VHS videotape and read by a single
reader.
Skin biopsies. Skin biopsies were performed at the
beginning and the end of one treatment period, preferably
the first period, soon after the vascular reactivity measure-ments. One 2-mm skin punch biopsy sample was taken
from the volar aspect of the forearm with the patient under
local anesthesia (1% plain lidocaine). The wound edges
were then approximated with sterile strips, and no sutures
were used. The specimens were snap-frozen in liquid nitro-
gen and then stored at 80°C until processing.
Histology and immunohistochemistry. Five-
micrometer cryosections were fixed with 2% paraformalde-
hyde in 10 mmol/L citrate buffer (pH 6.0) at 95°C.
Immunoreactivity of poly(adenosine diphosphate-ribose)
(PAR), the product of the PAR polymerase (PARP) en-
zyme in tissue sections, was measured by using a mouse
monoclonal anti-human PAR antiserum at 2 g/mL
(Alexis Biochemicals, San Diego, Calif), as previously de-
scribed.12 The expression of the receptor for advanced
glycation end products was assessed with goat polyclonal
antiserum at 1:600 dilution (Abcam, Cambridge, Mass).
Alternatively, sections were fixed with an acetone-based
buffer and stained for the expression of endothelial nitric
oxide synthase (eNOS) by using a rabbit anti-human eNOS
polyclonal antiserum at a final concentration of 1.5mg/mL
Table I. Clinical characteristics of participants
Variable
Non-DM
subjects T2DM
Total No. patients 13 13
Age (y) 54  10 53  13
No. men (%) 7 (54%) 7 (54%)
DM duration (y) — 9  7
BMI (kg/m2) 30.5  6.6 34.5  10.9
Systolic BP (mm Hg) 136  22 140  17
Diastolic BP (mm Hg) 74  8 74  12
Fasting glucose* (mg/dL) 80  9 127  71
HbA1c† 5.6  0.4 7.6  1.7
Total cholesterol (mg/dL) 200  33 187  40
LDL (mg/dL) 121  29 112  33
HDL (mg/dL) 52  13 48  19
Triglycerides (mg/dL) 143  54 213  185
Antihypertensive treatment (n) 3 8
Beta blockers 0 1
ACE inhibitors 0 7
Diuretics 3 2
Calcium antagonists 1 2
Diabetes treatment (n)
Diet only 3
Oral agents 7
Metformin 6
Glyburide 2
Pioglitazone/rosiglitazone 2/1
Insulin 3
Statins 1 3
Aspirin 1 1
DM, Diabetes mellitus; T2DM, type 2 diabetic patients; BMI, body mass
index; BP, blood pressure; HbA1c, glycosylated hemoglobin; LDL, low-
density lipoprotein; HDL, high-density lipoprotein; ACE, angiotensin-
converting enzyme.
Data are mean  SD unless otherwise noted.
*P  .05.
†P  .001.(Neomarker, Fremont, Calif); inducible nitric oxide syn-
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(M-19) at a concentration of 2 g/mL (Santa Cruz Bio-
technology, Santa Cruz, Calif); and the endothelial marker
CD31 by using a mouse anti-human CD31 monoclonal
antibody at a concentration of 1 g/mL (BD Pharmingen,
San Diego, Calif). Secondary antibodies included a biotin-
ylated horse anti-mouse immunoglobulin G (HL) used at
1:250 dilution, a biotinylated goat anti-rabbit immuno-
globulin G (HL) used at 1:200 dilution, and a biotinyl-
ated rabbit anti-goat immunoglobulin G (HL) used at
1:200 dilution (Vector, Burlingame, Calif). Sections were
visualized by using horseradish peroxidase–conjugated
avidin-biotin (DAKO, Glostrup, Denmark) and 3,3=-
diaminobenzidine (Vector) and counterstained with hema-
toxylin. Data were analyzed by two blinded investigators
(C.F. and a staff pathologist from the Beth Israel Deaconess
Medical Center). Sections were scored for the intensity of
staining: 0, absence of staining; 1, faint scattered staining;
2, moderate staining; and 3, intense staining.
Data analysis. The calculation of the size sample was
based on previous work in our unit. More specifically, we
have recently completed a prospective randomized double-
blinded parallel trial in which diabetic subjects were treated
with either troglitazone or placebo.5 The selection criteria
of one group of subjects in that study and the treatment
duration were very similar to those of the present study.
We chose to conduct a crossover prospective, random-
ized, double-blind, placebo-controlled study because this
design could provide reliable results with fewer subjects
than a prospective, randomized, double-blind, placebo-
controlled parallel study. Thus, on the basis of the results of
our previous study, we hypothesized that patients would
have a baseline brachial endothelial function of 5.1% 
Table II. Baseline measurements of vascular reactivity and
Variable
Resting brachial artery diameter (mm)
Flow-mediated dilation (% increase over baseline)
Nitroglycerin-induced dilation (% increase over baseline)
Resting blood flow before acetylcholine iontophoresis (V)
Blood flow after acetylcholine iontophoresis (V)
Resting blood flow before sodium nitroprusside iontophoresis (V)
Blood flow after sodium nitroprusside iontophoresis (V)
Carotid intima-medial thickness (mm)
ICAM (ng/mL)
VCAM (ng/mL)
Endothelin 1 (pg/mL)
TNF- (pg/mL)
hsCRP (mg/dL)
IL-6
Adiponectin
sCD40L (ng/mL)
PAI-1 antigen (ng/mL)
tPA antigen (ng/mL)
DM, Diabetes mellitus; T2DM, type 2 diabetic patients; NS, not significant;
TNF, tumor necrosis factor; hsCRP, high-sensitivity C-reactive protein; IL,
Data are presented as mean  SD or median (25th-75th percentiles).2.1%. We also accepted that a 2.2% improvement duringvalsartan treatment vs placebo would be clinically impor-
tant and that the standard deviation of the improvement
would be 3.0. In a crossover study, a sample of 17 subjects
would provide more than 80% statistical power. We ex-
pected a 15% attrition rate and thus planned to recruit 20
subjects in each group. The same number of patients, or
even fewer, was also found to be adequate to test the other
primary end points of the study: namely, changes in the skin
microcirculation.
The Minitab statistical package (Minitab Inc, State
College, Pa) for personal computers was used for the
statistical analysis. Power analysis was based on a 50% im-
provement in the endothelial function of themicrocirculation
andmacrocirculation at a 	 level of 80% and an  level of .005
(two sided). The analysis was performed with a parametric
test (ie, a paired t test) for normally distributed data and a
nonparametric test (ie, the Wilcoxon matched pair signed
rank test) for data that were not distributed normally, to
compare the changes during the placebo and active period
treatments in each group. The t test was used to compare
the baseline characteristics between the healthy nondia-
betic subjects and the T2DM patients. The results are
presented as mean  SD for normally distributed data and
median (25th-75th percentiles) for data that are not dis-
tributed normally. The 
2 test was used for analysis of the
skin biopsy data. Statistical significance was accepted at the
95% confidence level (P  .05).
RESULTS
Thirteen subjects out of 20 in each group completed
the study. Data obtained from these subjects were used for
statistical analysis. The main reasons for not completing
the study were loss to follow-up (two subjects), adverse
chemical markers of endothelial function
Non-DM subjects T2DM P value
4.1  0.7 4.1  0.4 NS
8.1  2.2 5.9  1.2 .004
15.3  2.5 13.4  2.0 .041
1.03  0.27 0.94  22 NS
1.92  0.49 1.67  0.41 NS
1.21  0.22 1.04  0.18 NS
1.75  0.38 1.55  0.35 NS
0.74 (0.62-0.82) 0.66 (0.61-0.73) NS
317  115 318  122 NS
602  160 543  164 NS
0.78  0.25 0.52  0.42 NS
1.93  0.63 2.21  1.17 NS
2.33 (0.76-6.90) 2.88 (1.28-5.94) NS
15.6  13.4 14.9  4.8 NS
4282 (1957-4664) 2675 (1587-5996) NS
4.8 (3.7-10.4) 2.5 (1.6-3.3) .001
74 (18-221) 74 (22-150) NS
3.6  2.7 4.0  1.8 NS
, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule;
eukin; PAI, plasma activator inhibitor; tPA, tissue plasminogen activator.bio
ICAM
interlevents not related to the study (five subjects), withdrawal of
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the study protocol; five subjects), and side effects from the
study medications (in the form of dizziness that resolved
after stopping the medication; two subjects, both with
T2DM). There were no differences between those who
completed the study and those who did not complete the
study in any of the clinical characteristics listed in Table I.
The baseline demographics of those who completed the
study in each group are shown in Table I. The results of the
baseline measurements of the vascular reactivity and bio-
chemical markers of endothelial dysfunction are shown in
Table II. The flow-mediated brachial artery dilation (endo-
thelium dependent) and the nitroglycerin-induced brachial
Table III. Changes between the initial and exit visit durin
diabetic group
Valsar
Variable Initial visit E
Systolic BP (mm Hg) 133  17 12
Diastolic BP (mm Hg) 73  11 7
Resting brachial artery diameter (mm) 4.0  0.5 4.
Flow-mediated dilation (% increase
over baseline) 6.2  1.2 6.
Nitroglycerin-induced dilation
(% increase over baseline) 14.1  3.4 14.
Resting blood flow before
acetylcholine iontophoresis (V) 0.90  0.34 1.2
Blood flow after acetylcholine
iontophoresis (V) 1.55  0.37 1.9
Resting blood flow before sodium
nitroprusside iontophoresis (V) 0.98  0.28 1.4
Blood flow after sodium nitroprusside
iontophoresis (V) 1.32  0.37 1.7
Carotid intima-medial thickness (mm) 0.69 (0.61-0.77) 0.70
BP, Blood pressure; NS, not significant.
Data are presented as mean  SD or median (25th-75th percentiles).
Table IV. Comparisons of changes during treatment with
Variable Va
Systolic BP (mm Hg) 5 (2
Diastolic BP (mm Hg) 5 (1
Resting brachial artery diameter (mm)
(measurements for both FMD and NID) 0.03 (0
FMD (% increase over baseline) 0.39 (1
NID (% increase over baseline) 0.19 (1
Resting blood flow before acetylcholine
iontophoresis (V) 0.51 (0.0
Blood flow after acetylcholine
iontophoresis (V) 0.20 (0.0
Resting blood flow before sodium
nitroprusside iontophoresis (V) 0.42 (0.1
Blood flow after sodium nitroprusside
iontophoresis (V) 0.41 (0.1
BP, Blood pressure; NS, not significant; FMD, flow-mediated brachial arter
Data are presented as median (25th-75th percentiles) and indicate changesartery dilation (endothelium independent) were reduced inthe diabetic groups when compared with the healthy non-
diabetic subjects.
Effect of valsartan on the blood flow and vascular
reactivity of diabetic patients. Seven patients received
placebo during the first 12-week period, and six received
treatment with valsartan. There were no differences be-
tween those who received placebo and those who received
valsartan during the first period.
The changes in vascular reactivity during the treatment
with valsartan and placebo are shown in Table III. Com-
paring the results of the initial visit and the exit visit during
treatment with valsartan, a significant increase was observed
in the resting skin blood flow in both skin areas that were
e valsartan and placebo period treatments in the
Placebo
sit P value Initial visit Exit visit P value
8 NS 134  18 123  1.15 NS
NS 75  13 72  4 NS
.7 NS 4.2  0.7 4.1  0.5 NS
.0 NS 5.8  1.5 5.99  1.4 NS
.4 NS 13.1  2.1 15.6  3.1 .029
.38 .002 0.98  0.20 0.98  0.21 NS
.48 .033 1.78  0.48 1.81  0.41 NS
.41 .001 1.12  0.26 1.08  0.25 NS
.51 .040 1.62  0.36 1.62  0.25 NS
-0.83) NS 0.66 (0.63-0.74) 0.68 (0.63-0.75) NS
artan and placebo in diabetic patients
n Placebo P value
12) 4 (36 to 13) NS
7) 3 (14 to 6) NS
o 0.22) 0.15 (0.30 to 0.14) .023
o 2.15) 0.02 (0.52 to 1.0) NS
o 1.26) 1.81 (0.2 to 5.69) NS
0.57) 0.03 (0.21 to 0.20) .025
0.72) 0.25 (0.18 to 0.38) NS
0.74) 0.02 (0.33 to 0.29) .041
0.63) 0.02 (0.24 to 0.31) .151
ion; NID, nitroglycerin-induced dilation.
indicated variables.g th
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sis of both acetylcholine and sodium nitroprusside were
higher at the exit visit when compared with the initial visit.
There were no differences between the patients who were
receiving ACE inhibitors during the study and those who
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addition, significant changes were noticed in the resting
skin blood flow at both skin areas that were used for the
iontophoresis of acetylcholine and sodium nitroprusside
and in the skin blood flow after the iontophoresis of sodium
nitroprusside. Thus, the resting skin blood flow increased
by 60% (2%-90%; median and 25th-75th percentiles) dur-
ing valsartan treatment in the area chosen for the ionto-
phoresis of acetylcholine, vs a 2% (22% to 27%) increase in
the same area during placebo treatment. Similar changes
were observed in the area of the sodium nitroprusside
iontophoresis (P  .05; Fig 2).
No differences were observed in the common carotid
artery intima-media thickness during the placebo and
valsartan treatment periods. There were also no differ-
ences in glycemia, lipid levels, or any other biochemical
markers of endothelial dysfunction with either valsartan
or placebo.
Effect of valsartan on blood flow and vascular
reactivity of healthy nondiabetic subjects. Seven sub-
jects received placebo during the first 12-week period, and
six received treatment with valsartan. There were no differ-
ences between those who received placebo and those who
received valsartan during the first period. The results of the
nondiabetic subjects are presented in Table V. In summary,
no changes were observed in any of the studied parameters
between the initial and exit visit whether the subjects were
receiving valsartan or placebo. As a result, no differences
were detected when valsartan was compared with placebo
treatment.
The only biochemical difference reported was higher
sCD40L levels at baseline in nondiabetic vs diabetic sub-
jects. This is consistent with the increased inflammatory
milieu and lower anti-inflammatory potential in diabetic
Table V. Changes between the initial and exit visit during
nondiabetic subjects
Variable Initial visit
Systolic BP (mm Hg) 136  23
Diastolic BP (mm Hg) 76  8
Resting brachial artery diameter (mm) 4.1  0.7
Flow-mediated dilation (% increase over baseline) 7.9  2.0
Nitroglycerin-induced dilation (% increase over
baseline) 16.3  2.0
Resting blood flow before acetylcholine
iontophoresis (V) 1.00  0.26
Blood flow after acetylcholine iontophoresis (V) 1.89  0.40
Resting blood flow before sodium nitroprusside
iontophoresis (V) 1.15  0.25
Blood flow after sodium nitroprusside
iontophoresis (V) 1.63  0.39
BP, Blood pressure; NS, not significant.
Data are presented as mean  SD. There were no differences between cha
presented parameters in this table.patients.Skin biopsy results. Skin biopsies were performed
during only one treatment period. Twenty-one participants
(10 T2DM and 12 nondiabetic healthy subjects) had biop-
sies at the beginning and the end of a given treatment
period. Twelve participants (5 T2DM) were receiving val-
sartan, and 10 participants (5 T2DM) were receiving pla-
cebo. The intensity of the immunostaining for the different
markers studied was recorded for all skin biopsy samples,
and the results obtained at the initial visit were compared
with those obtained at the exit visit (Fig 3).
The results of the skin biopsy analysis are shown in
F i g 4 . The immunostaining for PAR, the product of the
PARP enzyme and, therefore, a surrogate measurement of
PARP activity, was scored as described in “Materials and
Methods.” PAR immunostaining was reduced in six (50%)
valsartan-treated subjects, compared with none (0%) of the
placebo-treated subjects (P  .02; Fig 4, A). In addition,
the CD31 staining was increased in four (33%) valsartan-
treated subjects, compared with none (0%) in the placebo
group. This reached marginal statistical significance (P 
.057; Fig 4, B). Similar results were observed when diabetic
and nondiabetic subjects were analyzed separately, but
because of the small number of observations in each group,
no statistical significance was achieved (data not shown).
There were no changes in the difference of the staining
intensity for eNOS, iNOS, and receptor for advanced gly-
cation end products (data not shown).
DISCUSSION
The main finding of this study was that treatment with
valsartan increased the resting skin blood flow in T2DM
with no evidence of diabetic vascular complications. In
addition, treatment with valsartan increased the resting
brachial artery diameter, whereas no changes were observed
valsartan and placebo period treatments in the healthy
lsartan Placebo
Exit visit P value Initial visit Exit visit P value
30  24 NS 137  17 128  19 NS
1  12 NS 74  10 72  12 NS
.0  0.7 NS 4.1  0.6 4.0  0.7 NS
.5  1.6 NS 7.1  1.6 8.0  1.8 NS
.4  2.1 NS 15.1  2.2 15.8  2.0 NS
99  0.25 NS 1.10  0.30 1.09  0.17 NS
86  0.45 NS 1.96  0.74 1.88  0.44 NS
15  0.28 NS 1.34  0.38 1.26  0.24 NS
81  0.41 NS 1.91  0.58 1.74  0.33 NS
uring the valsartan treatment period and the placebo period in any of thethe
Va
1
7
4
7
16
0.
1.
1.
1.
nges din any of the endothelial activation biochemical measure-
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 4 Shrikhande et al 767ments. In contrast, no changes were observed in the vascu-
lar function of healthy nondiabetic subjects, thus indicating
that the observed results were related to diabetes-induced
changes. Finally, treatment with valsartan reduced PARP
activity, an enzyme that has been implicated in the devel-
opment of endothelial dysfunction.12 Because this was a
preliminary study that aimed to provide proof of concept
regarding the effects of the valsartan on the vascular reac-
tivity and the mechanisms related to these effects, further
studies will be required to confirm these findings before any
firm conclusions can be reached.
Most of the studies that have been published have
investigated the therapeutic potential of novel therapies for
vascular reactivity of large vessels such as the brachial or the
coronary arteries.4-7 To our knowledge, this is the first
Fig 3. Representative skin biopsy samples from two ty
placebo or valsartan and stained for poly(adenosine di
polymerase (PARP) enzyme and, therefore, a surrogate
reactivity. A, Results demonstrate intense staining (a
immunoreactivity remained as intense after treatment w
valsartan (original magnification,200). B,CD31 immu
dermal capillaries, was sparse before treatment in both pa
placebo. In contrast, significantly more CD31 staining w
cation, 100).study to show a beneficial effect of an ARB such as valsartanon the blood flow in the skin microcirculation of diabetic
patients. It is of interest that the improvement was mainly
detected in resting blood flow. Previous studies have shown
that treatment with ARBs increases the bioavailability of
nitric oxide, and this could certainly account for the results
obtained in this study.6 Thus, we have shown that valsartan
increases both endothelium-dependent and -independent
vasodilation, which is in line with a potential smooth mus-
cle response to nitric oxide.
Previous studies in our unit in comparable populations
of diabetic patients and using similar readouts have shown
that intervention with ACE inhibitors, thiazolidinediones,
statins, exercise, and antioxidants had no effects on the skin
microcirculation, including both resting skin blood flow
and blood flow after the iontophoresis of acetylcholine and
diabetic patients before and after treatment with either
phate [ADP]-ribose) (PAR), the product of the PAR
urement of PARP activity (A) and CD31 (B) immuno-
s) in both patients before treatment for PAR. PAR
lacebo but significantly decreased after treatment with
activity (arrows), indicative of endothelial cells and small
and remained so after treatment in the patient receiving
etected after treatment with valsartan (original magnifi-pe 2
phos
meas
rrow
ith p
nore
tients
as dsodium nitroprusside.5,13-16 In addition, in this study,
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were treated with ACE inhibitors and those who were not,
thus indicating that ACE inhibitors do not have any effect
on ARBs’ ability to increase blood flow in the skin micro-
circulation. Therefore, the ability of ARBs such as valsartan
to increase skin blood flow seems to be unique and is
probably related to a sustained inhibition of angiotensin II
actions on the blood vessel wall. Further studies will be
required to address this hypothesis.
The beneficial effects of valsartan were observed only in
diabetic patients: no effects were observed in the control
subjects. The reasons for these findings are still not clear but
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Fig 4. A, Differences in the PARP activity in forearm skin biopsy
samples taken before treatment initiation and after completion of a
12-week period of treatment either with valsartan (black columns)
or placebo (gray columns). Staining for poly(adenosine diphos-
phate-ribose) (PAR, the product of the PAR polymerase [PARP]
enzyme and, therefore, a surrogate measurement of PARP activity)
was characterized as reduced when the exit visit staining intensity
was scored as less than that of the initial visit, unchanged when the
intensity was similar in both visits, and increased when the intensity
was higher at the exit visit. The PAR staining was reduced in six
(50%) valsartan-treated subjects, whereas no reduction was ob-
served in none (0%) placebo-treated patients (P  .02). B, Differ-
ences in the CD31 staining in biopsy samples that were taken
before initiation of treatment and after completion of a 12-week
treatment period. Valsartan treatment (black columns) increased
the staining in four (33%) subjects as compared with no (0%)
placebo-treated subjects (gray columns), thus resulting in marginal
statistical significance (P  .057).may well relate to the presence in the diabetic population ofsubclinical inflammatory effectors that could be targeted by
valsartan. Participants from both groups were not hyper-
tensive at the beginning of the study, and no effects on the
blood pressure were observed during treatment with val-
sartan, as one could have expected from previous trials.17
This suggests that the observed results are probably related
to mechanisms that are independent from blood pressure
reduction. This is supported by other studies demonstrating
that blockade of the renin-angiotensin-aldosterone system
ameliorates the atherosclerotic process in diabetic animals
independently from blood pressure control.18,19 Angiotensin
II, in addition to its vasoconstrictor effects, promotes super-
oxide production via increased activity of NAD(P)H oxidase
and, hence, oxidative damage.20 Therefore, one can reason-
ably suggest that valsartan-mediated blockade of such oxi-
dative stress could, at least in part, account for the beneficial
results observed.
Recent studies have also shown that angiotensin II is
expressed by adipose tissue and that obesity activates the
renin-angiotensin-aldosterone system.21 ARB treatment
increases adiponectin levels in hypertensive subjects,
thus leading to the hypothesis that blockade of the
renin-angiotensin-aldosterone system could promote
differentiation of adipocytes and result in improvement
of insulin resistance.22 In addition, there is recent evi-
dence that ARBs decrease tissue factor activity and plasmin-
ogen activator inhibitor type 1 antigen and C-reactive
protein levels in hypertensive patients.23,24 In this study,
we did not detect any significant modification in cytokines
or other biochemical endothelial activation factors tested.
The reasons for this discrepancy are not known but may
well relate to the short duration of the study, the small
sample size, and the fact that the subjects were either
diabetic patients or healthy subjects and, thus, were at the
two ends of the spectrum in terms of endothelial cell
activation.
One major finding in the skin biopsy data analysis was
the reduction of PAR immunoreactivity and, hence, PARP
activity in valsartan-treated subjects. PARP is an abundant
nuclear enzyme that recognizes oxidative DNA damage
and triggers an inefficient cellular metabolic cycle, which
leads to cellular dysfunction that can ultimately culminate
in cell necrosis.25,26 Studies in animal models of diabetes
have suggested that activation of PARP causes endothelial
dysfunction and plays a pivotal role in the development of
long-term diabetes complications by various mechanisms,
including nicotinamide adenine dinucleotide depletion and
energy failure, changes in transcriptional regulation and
gene expression, and inhibition of the glyceraldehyde-3-
phosphate dehydrogenase enzyme activity.27,28 Studies in
our unit have also shown that PARP is activated not only in
T2DM, but also in healthy subjects at risk of developing
diabetes, and that PARP activation correlates with changes
in the skin blood flow.12 This is the first study in human
subjects to indicate that PARP activity can be reduced via a
therapeutic intervention. However, it should be pointed
out that PARP activity was reduced in both diabetic and
nondiabetic subjects, whereas the skin blood flow increased
JOURNAL OF VASCULAR SURGERY
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fully evaluate the relationship between ARB treatment,
PARP activation, and skin blood flow. Confirmation of the
observed results may have a considerable effect on thera-
peutic strategies aimed at improving endothelial function
and preventing the vascular complications of diabetes.
Other factors that have been related to endothelial
dysfunction in diabetes include reduced expression and
activity of eNOS and overexpression of receptor for ad-
vanced glycation end products that is linked to nuclear
factor-B activation.1,29-32 Our results indicate that valsar-
tan had no effect on these pathways. However, valsartan
treatment resulted in a marginal improvement in the stain-
ing of CD31, a protein that is exclusively expressed in
endothelial cells. Although the implications of this obser-
vation are not clear, further studies will be required to
examine whether valsartan treatment causes increased skin
blood flow by increasing capillary recruitment to the skin
microcirculation. Finally, the possibility that reduced PARP
activation is responsible for this increased capillary recruit-
ment should also be explored.
This study may have significant clinical implications.
Indeed, diabetic patients are at risk of developing foot
problems that carry significant morbidity and mortality.
Diabetic neuropathy is amajor etiologic factor that contrib-
utes to this problem through increased skin dryness and
reduced local hyperemia in response to tissue injury/
inflammation.1,33 It is our hypothesis that by improving
blood flow to the skin of diabetic patients, valsartan may
significantly affect the reduction of foot ulcers. However,
further studies are required before solid conclusions can be
reached.
We recognize that our study has some limitations. The
small number of participants in each group and the limited
duration of the study restrict our ability to identify other
potential mechanisms of action of valsartan. In addition, it
is not clear whether valsartan increases the resting diameter
of the brachial artery or simply prevents a decline in the
diameter, probably related to diabetes-related vasoconstric-
tion due to reduced nitric oxide bioavailability. Additional
studies will be required to answer this question. Further-
more, the diabetic patients studied were free of any severe
cardiovascular disease or long-term complications of diabe-
tes, and, as a result, the potential of valsartan to affect
already-established lesions cannot be accurately evaluated.
In addition, only 13 subjects in each group completed the
study instead of the 17 expected in our statistical power
calculation. However, we believe that this did not affect
our negative finding regarding the brachial artery flow–
mediated brachial artery dilation. Themain reason for this
is that although we hypothesized that the change in the
flow-mediated brachial artery dilation between active and
placebo treatments would be 2.2%, the actual observed one
was much smaller and, obviously, of no clinical importance
(0.37%; Table IV). Therefore, even if all subjects had
completed the study, the results would still be negative.
Finally, it should be emphasized that this is an initial study
aimed as a proof of concept of the potential benefit of thissafe drug for EC function in diabetes and that further
studies should be conducted before firm conclusions are
reached.
In summary, we have shown that a 12-week treatment
with valsartan increases the resting skin blood flow in T2DM
through mechanisms that are independent from reducing the
arterial blood pressure. In addition, treatment with valsartan
reduced the activity of PARP in the skinmicrovasculature, and
this could, at least in part, account for the observed results in
the skin blood flow measurements.
We thank Dr Shiva Gautam, PhD, statistician, for his
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Building on prior work demonstrating impaired microcircula-
tory autoregulation in diabetic patients, nondiabetic patients with
impaired glucose tolerance, and healthy patients at risk for diabe-
tes, Veves et al now demonstrate that angiotensin II receptor-
blocker (ARB) therapy increases diabetic resting skin blood flow in
response to both endothelium dependent and independent vaso-
dilator therapy. These reversals occurred in the absence of measur-
able blood pressure effects and were additive to and apparently
independent of angiotensin-converting enzyme (ACE) inhibition,
suggesting a potentially new regulatory mechanism. Poly(ade-
nosine diphosphate ribose) polymerase (PARP), an enzyme linked
to diabetic vascular dysfunction, was also inhibited. Readers who
want additional background on the methods and implications of
this type of microcirculatory research should refer to the excellent
recent review by Abularrage et al (J Vasc Surg 2005;42:574-81).
Endothelial dysfunction and insulin resistance are synergisticclinical metabolic syndrome, impaired glucose tolerance, and dia-
betes, oxidative stress and inflammation accelerate the evolution of
endothelial dysfunction into atherosclerosis. Clinical evidence al-
ready suggests that renin angiotensin aldosterone system (RAAS)
blockade reduces the risk of progression from insulin resistance to
type 2 diabetes mellitus. As a relatively new class of antihyperten-
sive agents, ARBs also promote dose-dependant reductions in
platelet activation and aggregation and reduce proinflammatory
serum tumor necrosis factor- and interleukin-6 levels in vascular
patients, although reductions in proinflammatory biomarkers were
not achieved in the present study. Intriguingly, these benefits seem
to be accentuated in diabetic patients. Valsartan also restores
endothelium-dependent cerebral arterial vasodilation after expo-
sure to cigarette smoke. Despite this remarkable range of potential
therapeutic benefit, it is unclear whether ARBs improve clinical
cardiovascular outcomes beyond the benefit achieved by their
antihypertensive effects alone.
